Cook Launches 140-mm Zilver PTX Stent in Europe


March 1, 2017—Cook Medical announced the launch of the 140-mm Zilver PTX paclitaxel-eluting stent in Europe. The addition to the company's Zilver PTX product portfolio allows for the treatment of longer lesions with just one stent. The device is deployed via a thumbwheel delivery system.

The Zilver PTX drug-eluting stent is indicated for the treatment of superficial femoral artery disease and has been demonstrated to reduce restenosis and reinterventions by approximately 50% over 5 years compared to Cook's Zilver bare-metal stents and percutaneous transluminal angioplasty.

In March 2016, the 5-year results of the Zilver PTX randomized controlled trial were published by Michael D. Dake, MD, et al online ahead of print in Circulation. The clinical trial confirmed long-term patency for patients treated with the Zilver PTX for peripheral artery disease in femoropopliteal arteries.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.